GlassScriptPhysician profile
Ali M Safa
NPI 1952475048
$4,360.52
in general payments reported to CMS, 2019-2025
32 companies · $466 in 2025
The $466 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $198 · 2021: $494 · 2022: $959 · 2023: $987 · 2024: $710 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,131 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,130.93 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,079.73 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $726.64 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $334.04 | 2023-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $195.41 | 2019-2023 | |
| Medtronic Minimed, INC. | $181.62 | 2019-2020 | |
| Abbvie INC. | $170.07 | 2019-2025 | |
| Echosens North America, INC. | $159.60 | 2023 | Fibroscan |
| Abbott Laboratories | $146.16 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.77 | 2019-2025 | Jardiance |
| Medtronic, INC. | $128.84 | 2021-2024 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Tandem Diabetes Care, INC. | $114.78 | 2020-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $112.76 | 2022-2024 | Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $109.64 | 2024-2025 | Unithroid |
| Insulet Corporation | $100.23 | 2019-2025 | Omnipod |
| Dexcom, INC. | $84.56 | 2019-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $65.35 | 2019-2022 | |
| Horizon Therapeutics Plc | $59.72 | 2021-2023 | Tepezza |
| Zealand Pharma US, INC. | $59.23 | 2021-2022 | |
| Lifescan, INC. | $45.92 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $44.58 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $43.35 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $41.50 | 2019-2023 | Verquvo |
| Amarin Pharma, INC. | $37.87 | 2019-2022 | |
| Companion Medical, INC. | $33.87 | 2019 | |
| Esperion Therapeutics, INC. | $32.17 | 2021 | |
| Corcept Therapeutics | $22.10 | 2019 | |
| Acerus Pharmaceuticals Corporation | $18.59 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.55 | 2022 | |
| Currax Pharmaceuticals LLC | $14.95 | 2023 | Contrave |
| Astrazeneca Pharmaceuticals LP | $14.49 | 2019 | |
| Astellas Pharma US INC | $14.45 | 2025 | Veozah |
| Antares Pharma, INC. | $13.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Safa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.